Progenics Pharmaceuticals (PGNX) Posts Quarterly Results
Progenics Pharmaceuticals (NASDAQ:PGNX) announced its earnings results on Friday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.03, AmericanBankingNews.com reports. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $2.83 million.
Progenics Pharmaceuticals (NASDAQ:PGNX) opened at 4.62 on Friday. Progenics Pharmaceuticals has a 52-week low of $3.10 and a 52-week high of $7.45. The stock’s 50-day moving average is $4.57 and its 200-day moving average is $4.34. The company’s market cap is $321.3 million.
Progenics Pharmaceuticals, Inc (NASDAQ:PGNX) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.